Clenbuterol vs PT-141
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Clenbuterol and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Clenbuterol PT-141
Weight 277.19 Da —
Half-life ~36 hours ~2.7 hours
Type Sympathomimetic amine (C12H18Cl2N2O) Melanocortin receptor agonist
Key Benefits
Clenbuterol
01 Increased basal metabolic rate and thermogenesis for accelerated fat loss
02 Preferential mobilization of stored body fat through enhanced lipolysis
03 Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
04 Bronchodilation and improved respiratory capacity during intense exercise
05 Appetite suppression in many users, supporting adherence to caloric deficit
06 Oral administration with no injections required
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Clenbuterol
20-120 mcg/day / Once daily (morning)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Clenbuterol
Tremors and shaking (especially hands) - most pronounced in the first 3-5 days
Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)
Insomnia and sleep disturbance, particularly with afternoon or evening dosing
Muscle cramps (calves, forearms, back) due to taurine depletion
Increased sweating and elevated body temperature
Headaches, particularly during dose ramp-up
Nervousness, anxiety, and restlessness
Increased blood pressure
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia
Uncontrolled hypertension
Hyperthyroidism or thyrotoxicosis
Hypokalemia or electrolyte imbalances
Known hypersensitivity to clenbuterol or sympathomimetic amines
Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors
Pregnancy or breastfeeding
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Clenbuterol PT-141
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest 2021 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.